Publications

525Mo Updated Efficacy and Safety of Lenvatinib (Len) + Pembrolizumab (Pembro) Vs Treatment of Physician’s Choice (Tpc) in Patients (Pts) with Advanced Endometrial Cancer (Aec): Study 309/Keynote-775

AuthID
P-00Y-B6B

Author(s)

Makker, V

Colombo, N

Casado Herraez, A

Monk, B

Mackay, H

Santin, A

Miller, D

Moore, R

Baron-Hay, S

Ray-Coquard, I

Shapira-Frommer, R

Ushijima, K

Yonemori, K

Kim, Y

Guerra Alia, E

Sanli, U

Huang, J

McKenzie, J

Barresi, G

Lorusso, D

Document Type

Article

Year published

2022

Published

in Annals of Oncology, ISSN: 0923-7534

Volume: 33, Pages: S785-S786

Indexing

Crossref^®1

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2022.07.653

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

525Mo Updated Efficacy and Safety of Lenvatinib (Len) + Pembrolizumab (Pembro) Vs Treatment of Physician’s Choice (Tpc) in Patients (Pts) with Advanced Endometrial Cancer (Aec): Study 309/Keynote-775

Useful Links

Get Help

Federated Authentication (Click on the image)

525Mo Updated Efficacy and Safety of Lenvatinib (Len) + Pembrolizumab (Pembro) Vs Treatment of Physician’s Choice (Tpc) in Patients (Pts) with Advanced Endometrial Cancer (Aec): Study 309/Keynote-775

Useful Links

Get Help